Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 2:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 426 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Relapsing Multiple Sclerosis Clear all
Active, not recruiting Phase 3 Interventional

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

NCT06869785
View directory record Official record
Conditions
Relapsing Multiple Sclerosis (RMS)
Interventions
Ofatumumab approved dose, Ofatumumab new dose
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
63
States / cities
Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 51 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 21, 2026, 2:18 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

NCT03870763
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Dimethyl Fumarate, Peginterferon Beta-1a, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
10 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jul 21, 2026, 2:18 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

NCT01252355
View directory record Official record
Conditions
Multiple Sclerosis Relapse
Interventions
Teriflunomide, Placebo (for teriflunomide), Interferon-beta (IFN-beta)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
32
States / cities
Cullman, Alabama • Cordova, Alaska • Phoenix, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Jul 21, 2026, 2:18 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.

NCT02833714
View directory record Official record
Conditions
RELAPSING REMITTING MULTIPLE SCLEROSIS
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Phase 1 Interventional

Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis

NCT00645749
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Helminth ova
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Jul 21, 2026, 2:18 PM EDT
Withdrawn No phase listed Observational

Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS

NCT02419638
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rebif (IFN β-1a subcutaneous three times per week), Tecifdera (dimethyl fumarate)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

NCT00676715
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Placebo, Ocrelizumab, Avonex
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
26
States / cities
Phoenix, Arizona • Berkeley, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Jul 21, 2026, 2:18 PM EDT
Completed No phase listed Observational

Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS

NCT01903291
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
62
States / cities
Birmingham, Alabama • Tuscon, Arizona • Los Angeles, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2016 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Results available

Treatment Interruption of Natalizumab

NCT01071083
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
natalizumab, interferon beta 1-a, methylprednisolone, IV placebo, glatiramer acetate
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Cullman, Alabama • San Francisco, California • Fort Collins, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2013 · Synced Jul 21, 2026, 2:18 PM EDT
Recruiting Phase 1 Interventional

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

NCT07304154
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis
Interventions
KITE-363, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Palo Alto, California • New York, New York • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Phase 4 Interventional Results available

Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409

NCT02255656
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
alemtuzumab GZ402673
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
1,062 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
52
States / cities
Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Results available

A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients

NCT03560739
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ofatumumab with PRF, ofatumumab with AI
Combination Product
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Fullerton, California • Aurora, Colorado • Basalt, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Jul 21, 2026, 2:18 PM EDT
Terminated Phase 1 Interventional

A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

NCT01144351
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ELND002, Placebo
Drug
Lead sponsor
Elan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
17
States / cities
Berkeley, California • Fresno, California • Newport Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis

NCT01585766
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing Forms
Interventions
MEDI-551 30 MG-IV, MEDI-551 60 MG-SC, PLACEBO-IV-SC, MEDI-551 100 MG-IV, MEDI-551 300 MG-SC, MEDI-551 600 MG-IV
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Scottsdale, Arizona • Long Beach, California • Sacramento, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2018 · Synced Jul 21, 2026, 2:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis

NCT02021162
View directory record Official record
Conditions
Multiple Sclerosis, Healthy
Interventions
Not listed
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Phase 3 Interventional Results available

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)

NCT00835770
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
dimethyl fumarate, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
19 Years to 58 Years
Enrollment
1,736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
50
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Jul 21, 2026, 2:18 PM EDT
Terminated Phase 3 Interventional Results available

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis

NCT01058005
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
BG00002 (natalizumab), interferon beta-1a, glatiramer acetate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
19
States / cities
Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2014 · Synced Jul 21, 2026, 2:18 PM EDT
Terminated Phase 3 Interventional Results available

Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)

NCT02907177
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ponesimod, Placebo
Drug · Other
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 55 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
26
States / cities
Birmingham, Alabama • Fresno, California • Pasadena, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Results available

Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis

NCT02738775
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ublituximab, Placebo
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
12
States / cities
Phoenix, Arizona • Pasadena, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Phase 3 Interventional Results available

An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

NCT04353492
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ofatumumab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
25
States / cities
Fullerton, California • Aurora, Colorado • Newark, Delaware + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Phase 3 Interventional Results available

A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study

NCT01036165
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
RebiSmart™
Device
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Jul 21, 2026, 2:18 PM EDT
Active, not recruiting Phase 4 Interventional

Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

NCT04466150
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
Interventions
Ocrelizumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Phase 4 Interventional Results available

A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

NCT04667117
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Quadrivalent influenza vaccine, Ofatumumab, iDMT
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Phoenix, Arizona • Hollywood, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Jul 21, 2026, 2:18 PM EDT
Not yet recruiting Phase 4 Interventional

A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy

NCT07609719
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
OCR SC
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
10
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fort Collins, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 21, 2026, 2:18 PM EDT